share_log

Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target

Moomoo 24/7 ·  Apr 3 12:02

Piper Sandler analyst Edward Tenthoff reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and maintains $13 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment